Shares of CME Group Inc. (NASDAQ:CME) opened at $139.57, and ended -0.43% lower at $139.49. Nearly 0.92 million shares were traded by the close, lower than its average daily volume of 1.17 million shares.CME Group Inc. (CME) Analyst Opinion
CME Group Inc. has a consensus outperform rating from 14 Wall Street analysts, and the number of shares currently sold short amount to at least 1.35% of shares outstanding. The stock spiked 3.36% last month and is up 20.93 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover CME having a buy-equivalent rating. Analysts have placed a $146.83 price target on CME Group Inc., suggesting a 5.26% gain from recent close. It’s currently trading about -1.38% below its 52-week high.CME Group Inc. Earnings Surprise
CME Group Inc. (CME) surprised the stock market in its last reported earnings when it earned $1.19 a piece versus the consensus-estimated $1.16. Its revenue totaled $892.45 million down -3.48% from the previous quarter.CME Group Inc. (NASDAQ:CME) Intraday View
This stock (CME) is ahead of its 52-week low with 28.92%. Its last month’s stock price volatility remained 1.34% which for the week stands at 1.52%. The share price has moved forward from its 20 days moving average, trading at a distance of 1.41% and stays 2.74% away from its 50 days moving average. Over the last five days, shares have managed 1.17% gains and now is up 11.46% since hitting its 200-day moving average of $127.14. CME Group Inc. (CME) has made its way to a 12-month gain of 24.11%.
Turning to AnaptysBio, Inc. (NASDAQ:ANAB), its shares were trading at $76.64 a gain of $1.78, on the trading floor. The stock, after opening at $74.54, touched a high of $79.18 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.3. AnaptysBio, Inc. has 4 buy ratings, 0 holds and 0 sells even after the stock tumbled -2.96% from its high of $78.98 to a $1.8 billion market value through last close.AnaptysBio, Inc. (ANAB) Consensus Price Target
The company’s consensus rating on Reuter’s scale improved from 1.4 to 1.5 during a month. Analysts set a 12-month price target of $83.71 a share. The target implies a 9.22% spike from where the shares are currently trading. Also, the current price highlights a discount of 50.05% to analysts’ high consensus price target.AnaptysBio, Inc. (NASDAQ:ANAB) Intraday Trading
The counter witnessed a trading volume of 0.34 million shares versus an average volume of 0.44 million shares during last trading session. Its last month’s stock price volatility remained 6.83% which for the week approaches 5.03%. The lowest price the stock reached in the last trading day was $74.54 and compares with the $15.17 52-week low. The stock recovered 405.21% since its low point and has performed 350.82% year-to-date.